Gland Pharma IPO is one of the fastest-growing generic injectable companies and is all set to make a debut in the stock market with an issue size of 6479.55 Cr.
Gland Pharma IPO– Overview
| GLAND PHARMA IPO Issue Date | 9-11 November 2020 |
| GLAND PHARMA IPO Opening Date | 9 Nov 2020 |
| GLAND PHARMA IPO Face Value | INR 1 per share |
| GLAND PHARMA IPO Price | INR 1500 per share |
| GLAND PHARMA IPO Lot Size | 10 Shares |
| Issue Size | 6479.55 Cr |
| Offer for sale | 5,229.55 Cr |
| Issue Type | Book built Issue IPO |
| Listing At | BSE, NSE |
| QIB Shares Offered | 6.40 times |
| NII (HNI) Shares | 0.51 times |
| Company Promoters | Fosun Pharma Industrial Pte. Ltd and Shanghai Fosun Pharmaceutical (Group) Co. Ltd is the company promoters. |
IPO Tentative Dates
| GLAND PHARMA IPO opening date | 9 Nov 2020 |
| GLAND PHARMA IPO closing date | 11 Nov 2020 |
| Basis of Allotment | 17 Nov 2020 |
| Initiation of Refunds | 18 Nov 2020 |
| The credit of Shares to Demat | 19 Nov 2020 |
| GLAND PHARMA IPO Listing Date | 20 Nov 2020 |
Industry Overview.
According to the IQVIA Report, the global formulation market grew at a CAGR of approximately 5.8% from 2014 to reach US$1,096 billion in 2019. The market is estimated to grow at a CAGR of 4.4% to reach US$1,359 billion by 2024.
Company Overview
It is one of the largest and fastest-growing injectable-focused companies in the United States of America from 2014-2019. The company has a portfolio of injectable products across various therapeutic areas and delivery systems.
Objectives Of The Issue
- To finance the incremental working capital requirements of our Company
- To meet funding requirements for capital expenditure requirements
- To meet the general corporate purposes
Financial Statements
| Particulars | 30-Sept-20 | 31-Mar-20 | 31-Mar-19 |
| Total Assets | 46,912.65 | 40,860.39 | 35,235.49 |
| Total Revenue | 9,162.89 | 27,724.08 | 21,297.67 |
| Profit After Tax | 3,135.90 | 7,728.58 | 4,518.56 |
Strengths
- The extensive product portfolio of complex injectables.
- Diversified B2B model with a targeted B2C model in India.
- Strong manufacturing capabilities.
- Robust financial track record.
- Experienced and qualified managerial team.
Weakness
- If its API production is interrupted or it fails to produce or procure high-quality APIs in the quantities it requires in a cost-effective manner, sales of its products could be delayed or interrupted.
- It is susceptible to product liability claims and associated risks of litigation that could expose it to material liabilities, loss in revenues, and increased expenses and thus may have a material adverse effect on its business.
Company Contact Information
Gland Pharma Limited
Sy. No. 143 – 148, 150 and 151,
Near Gandi Maisamma ‘X’ Roads, D.P. Pally,Dundigal
Medchal-Malkajgiri District, Hyderabad
Phone: +91 40 3051 0999
Email: investors@glandpharma.com
Website: http://www.glandpharma.com
IPO Registrar
Link Intime India Private Ltd
Phone: +91-22-4918 6270
Email: glandpharma.ipo@linkintime.co.in
Website: https://linkintime.co.in/
